Skip to main content
SpringerLink
Log in

Will angiogenic growth factors be the answer for inoperable CAD?

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sellke FW, Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs 1999 Sep; 58(3): 391–6

    Article  PubMed  CAS  Google Scholar 

  2. Stegmann TJ. New approaches to coronary heart disease: induction of neovascularisation by growth factors. BioDrugs 1999 May; 11(5): 301–8

    Article  PubMed  CAS  Google Scholar 

  3. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischaemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease. Circulation 1998; 97(7): 645–50

    Article  PubMed  CAS  Google Scholar 

  4. Sellke FW, Laham RJ, Edelman R, et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65: 1540–4

    Article  PubMed  CAS  Google Scholar 

  5. Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary artery bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999 Nov 2; 100(18): 1865–71

    Article  PubMed  CAS  Google Scholar 

  6. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardia; ischemia. Circulation 1998 Dec 22–29; 98(25): 2800–4

    Article  PubMed  CAS  Google Scholar 

  7. Henry T, Rocha-Singh K, Isner J, et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial [abstract]. J Am Coll Cardiol 1998; 31 Suppl. 2A: 65A

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Will angiogenic growth factors be the answer for inoperable CAD?. Drugs Ther. Perspect 15, 5–7 (2000). https://doi.org/10.2165/00042310-200015080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200015080-00002

Keywords

Search

Navigation